{"filing":{"accession_number":"0001104659-26-110608","cik":"0001333141","ticker":"FMCQF","company_name":"Fresenius Medical Care AG","form":"6-K","filing_date":"2026-09-25","report_date":"2026-09-25","primary_document":"tm2626162d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1333141/000110465926110608/tm2626162d1_6k.htm"},"events":[{"id":35017,"run_id":32247,"accession_number":"0001104659-26-110608","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Fresenius Medical Care announced a strategic refinement of its China commercial operations, including discontinuation of the 4008A hemodialysis system and exit from the peritoneal dialysis business, coupled with one-time charges of approximately €110 million (primarily impairment and termination costs) to be recognized in Q3 2026. This is a material operational and strategic business decision affecting a significant market segment (6-7% of Care Enablement revenues) with quantifiable financial impact, but does not fit the specific categories of workforce_reduction, material_impairment (standalone), or ma_activity; it is best classified as a material operational restructuring with strategic portfolio optimization.","company_name":"Fresenius Medical Care AG","ticker":"FMCQF","filing_date":"2026-09-25","form":"6-K","submitted_at":null,"items":[{"id":38933,"accession_number":"0001104659-26-110608","item_number":"EX-99.1","item_title":"tm2626162d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Fresenius Medical Care announced a strategic refinement of its China commercial operations, including discontinuation of the 4008A hemodialysis system and exit from the peritoneal dialysis business, coupled with one-time charges of approximately €110 million (primarily impairment and termination costs) to be recognized in Q3 2026. This is a material operational and strategic business decision affecting a significant market segment (6-7% of Care Enablement revenues) with quantifiable financial impact, but does not fit the specific categories of workforce_reduction, material_impairment (standalone), or ma_activity; it is best classified as a material operational restructuring with strategic portfolio optimization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-25T11:54:43.915951+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38933,"accession_number":"0001104659-26-110608","item_number":"EX-99.1","item_title":"tm2626162d1_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Fresenius Medical Care announced a strategic refinement of its China commercial operations, including discontinuation of the 4008A hemodialysis system and exit from the peritoneal dialysis business, coupled with one-time charges of approximately €110 million (primarily impairment and termination costs) to be recognized in Q3 2026. This is a material operational and strategic business decision affecting a significant market segment (6-7% of Care Enablement revenues) with quantifiable financial impact, but does not fit the specific categories of workforce_reduction, material_impairment (standalone), or ma_activity; it is best classified as a material operational restructuring with strategic portfolio optimization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-25T11:54:43.915951+00:00","company_name":"Fresenius Medical Care AG","ticker":"FMCQF","filing_date":"2026-09-25"}]}